English  |  正體中文  |  简体中文  |  總筆數 :0  
造訪人次 :  52536286    線上人數 :  711
教育部委託研究計畫      計畫執行:國立臺灣大學圖書館
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
關於TAIR

瀏覽

消息

著作權

相關連結

"lin z z"的相關文件

回到依作者瀏覽
依題名排序 依日期排序

顯示項目 226-250 / 330 (共14頁)
<< < 5 6 7 8 9 10 11 12 13 14 > >>
每頁顯示[10|25|50]項目

機構 日期 題名 作者
臺大學術典藏 2020-05-25T01:32:58Z Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations YEN-TING LIN; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏 2020-05-20T05:11:42Z Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations Yu C.-J.;Yang J.C.-H.;Shih J.-Y.;Lin Z.-Z.;Lee J.-H.;Chen K.-Y.;Yang C.-Y.;Hsu C.-L.;Ho C.-C.;Liao W.-Y.;Chen J.-S.;YEN-TING LIN; YEN-TING LIN; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏 2020-05-20T04:46:48Z Development and validation of nomograms for predicting survival probability of patients with advanced adenocarcinoma in different EGFR mutation status MING-CHIN YANG; Lin Z.-Z.; Liao C.-H.; Tan E.C.-H.; Chen H.-C.; Ming-Chin Yang;Lin Z.-Z.;Liao C.-H.;Tan E.C.-H.;Chen H.-C.
臺大學術典藏 2020-04-28T07:25:39Z Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphoma Huang C.-L.;Lin Z.-Z.;Su I.-J.;Chao T.-Y.;Tien H.-F.;Chang M.-C.;Huang M.-C.;Kao W.-Y.;Tang J.-L.;Yeh K.-H.;Wang C.-H.;Chih-Hung Hsu;Liu M.-Y.;Cheng A.-L.; Huang C.-L.; Lin Z.-Z.; Su I.-J.; Chao T.-Y.; Tien H.-F.; Chang M.-C.; Huang M.-C.; Kao W.-Y.; Tang J.-L.; Yeh K.-H.; Wang C.-H.; CHIH-HUNG HSU; Liu M.-Y.; Cheng A.-L.
臺大學術典藏 2020-04-28T07:25:30Z Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H.; CHIH-HUNG HSU; Yu C.-J.; Chang Y.-C.; Hsu C.; Yang C.-H.;Yang P.-C.;Cheng A.-L.;Lin C.-C.;CHIH-HUNG HSU;Yu C.-J.;Chang Y.-C.;Hsu C.;Lin Z.-Z.; Lin Z.-Z.
臺大學術典藏 2020-04-28T07:25:28Z Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; Cheng A.-L.; Shen Y.-C.; CHIH-HUNG HSU; Chih-Hung Hsu;Shen Y.-C.;Lin Z.-Z.;Chen P.-J.;Shao Y.-Y.;Ding Y.-H.;Hsu C.;Cheng A.-L.
臺大學術典藏 2020-04-28T07:25:28Z Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma Chih-Hung Hsu;Yang T.-S.;Hsu C.;Toh H.C.;Epstein R.J.;Hsiao L.-T.;Chen P.-J.;Lin Z.-Z.;Chao T.-Y.;Cheng A.-L.; CHIH-HUNG HSU; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L.
臺大學術典藏 2020-04-28T07:25:27Z Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma Shao Y.U.-Y. ;Chen P.-J. ;Lin Z.-Z. ;Huang C.-C. ;Ding Y.-H. ;Lee Y.-H. ;Chih-Hung Hsu ;Cheng A.-L.; Shao Y.U.-Y.; Chen P.-J.; Lin Z.-Z.; Huang C.-C.; Ding Y.-H.; Lee Y.-H.; CHIH-HUNG HSU; Cheng A.-L.
臺大學術典藏 2020-04-28T07:25:27Z Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma Shao Y.-Y.;Lin Z.-Z.;Hsu C.;Shen Y.-C.;Chih-Hung Hsu;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; CHIH-HUNG HSU; Cheng A.-L.
臺大學術典藏 2020-04-28T07:25:25Z High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy Shao Y.-Y. ;Lin Z.-Z. ;Chen T.-J. ;Hsu C. ;Shen Y.-C. ;Chih-Hung Hsu ;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Hsu C.; Shen Y.-C.; CHIH-HUNG HSU; Cheng A.-L.
臺大學術典藏 2020-04-28T07:25:13Z Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy Shao Y.-Y.; Shao Y.-Y.;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Chih-Hung Hsu;Wang M.-J.;Cheng A.-L.;Hsu C.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; CHIH-HUNG HSU; Wang M.-J.; Cheng A.-L.; Hsu C.
臺大學術典藏 2020-04-28T07:25:08Z A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy Lin Z.-Z.;Chen B.-B.;Hung Y.-P.;Huang P.-H.;Shen Y.-C.;Shao Y.-Y.;Chih-Hung Hsu;Cheng A.-L.;Lee R.-C.;Chao Y.;Hsu C.; Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; CHIH-HUNG HSU; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C.
臺大學術典藏 2020-04-10T12:51:23Z Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment Yang C.-H.; Yang P.-C.; Cheng A.-L.; Lin C.-C.; Hsu C.-H.; Yu C.-J.; Chang Y.-C.; Chiun Hsu; Lin Z.-Z.
臺大學術典藏 2020-04-10T12:51:22Z Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival Cheng A.-L.; Shen Y.-C.; Hu F.-C.; Jeng Y.-M.; Chang Y.-T.; Lin Z.-Z.; Chang M.-C.; Chiun Hsu
臺大學術典藏 2020-04-10T12:51:21Z The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma Lin Z.-Z.;Hsu H.-C.;Hsu C.-H.;Yeh P.-Y.;Huang C.-Y.F.;Huang Y.-F.;Chen T.-J.;Kuo S.-H.;Chiun Hsu;Hu F.-C.;Jeng Y.-M.;Chung Y.;Cheng A.-L.; Lin Z.-Z.; Hsu H.-C.; Hsu C.-H.; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; Kuo S.-H.; Chiun Hsu; Hu F.-C.; Jeng Y.-M.; Chung Y.; Cheng A.-L.
臺大學術典藏 2020-04-10T12:51:20Z Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma Hsu C.-H.;Yang T.-S.;Chiun Hsu;Toh H.C.;Epstein R.J.;Hsiao L.-T.;Chen P.-J.;Lin Z.-Z.;Chao T.-Y.;Cheng A.-L.; Hsu C.-H.; Yang T.-S.; Chiun Hsu; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L.
臺大學術典藏 2020-04-10T12:51:19Z Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma Hsu C.-H.;Shen Y.-C.;Lin Z.-Z.;Chen P.-J.;Shao Y.-Y.;Ding Y.-H.;Chiun Hsu;Cheng A.-L.; Hsu C.-H.; Shen Y.-C.; Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Chiun Hsu; Cheng A.-L.
臺大學術典藏 2020-04-10T12:51:17Z Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma Shao Y.-Y.;Lin Z.-Z.;Chiun Hsu;Shen Y.-C.;Hsu C.-H.;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Chiun Hsu; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2020-04-10T12:51:16Z High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy Shao Y.-Y. ;Lin Z.-Z. ;Chen T.-J. ;Chiun Hsu ;Shen Y.-C. ;Hsu C.-H. ;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Chiun Hsu; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2020-04-10T12:51:15Z Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma Cheng A.-L.; Hsu C.-H.; Lin Z.-Z.; Chiun Hsu; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Shao Y.-Y.
臺大學術典藏 2020-04-10T12:51:14Z Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy Lin Z.-Z.; Chiun Hsu; Hu F.-C.; Shao Y.-Y.; Chang D.-Y.; Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L.
臺大學術典藏 2020-04-10T12:51:13Z Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems Shao Y.-Y.; Lu L.-C.; Lin Z.-Z.; Chiun Hsu; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2020-04-10T12:51:11Z A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy Shao Y.-Y.; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Chiun Hsu; Cheng A.-L.; Lin Z.-Z.
臺大學術典藏 2020-04-10T12:51:10Z Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer Su W.-C.; Chao Y.; Yeh K.-H.; Cheng A.-L.; Chen L.-T.; Lin Z.-Z.; Shen Y.-C.; Li C.-P.; Yen C.-J.; Chiun Hsu; Lin Y.-L.; Shen Y.-C.;Li C.-P.;Yen C.-J.;Chiun Hsu;Lin Y.-L.;Lin Z.-Z.;Chen L.-T.;Su W.-C.;Chao Y.;Yeh K.-H.;Cheng A.-L.
臺大學術典藏 2020-04-10T12:51:10Z Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size Lin Z.-Z.; Shau W.-Y.; Chiun Hsu; Shao Y.-Y.; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S.

顯示項目 226-250 / 330 (共14頁)
<< < 5 6 7 8 9 10 11 12 13 14 > >>
每頁顯示[10|25|50]項目